Spinal Muscular Atrophy is a genetic neuromuscular disorder caused by SMN1 mutations, leading to insufficient survival motor neuron protein and progressive motor-neuron loss and muscle atrophy. Stem-cell research explores neurogenic cells to support or replace motor neurons and placental mesenchymal stem cells to secrete neuroprotective factors and reduce neuroinflammation. Because SMA is genetic, cellular approaches that do not correct the underlying SMN deficiency may offer limited long-term benefit. This distinguishes SMA from acquired disorders, and helps explain why approved gene-targeted therapies dominate care. Trials are very few; reported outcomes focus on motor-function stabilisation rather than recovery.
Five registered trials and 1 recruiting study address stem-cell therapy in SMA — the smallest landscape among the conditions here. Published data are sparse and largely single-centre observational. Some describe stabilisation or slowed decline over 6–12 months; others minimal change. SMA's rapid natural progression makes any stability potentially notable, but separating stem-cell effects from approved disease-modifying therapies (nusinersen, gene therapy) is difficult without controls. No trial has reversed motor-neuron loss.
Indicative costs, where offered, are roughly €4,500–€7,500 per course — availability is limited given sparse evidence. For context, approved SMA disease-modifying therapies are extremely expensive but insurance-covered and proven, which sets a high bar: a stem-cell approach would need to match their benefit to justify out-of-pocket cost. The figure is indicative only.
Cell therapy for Spinal Muscular Atrophy is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Spinal Muscular Atrophy programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Spinal Muscular Atrophy overview · Spinal Muscular Atrophy cost →
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită